Among advanced NSCLC without driver alterations, the available drugs are classified into three therapeutic classes: cytotoxic agents (e.g., pemetrexed, albumin paclitaxel, cisplatin, carboplatin, gemcitabine, and S-1), angiogenesis inhibitors (e.g., bevacizumab and anlotinib), and immunotherapy (e.g., anti-PD-1, pembrolizumab, tislelizumab, nivolumab, camrelizumab, sintilimab, toropalimab, anti-PD-L1, and atezolizumab) (3, 4). This evidence concerns the gene CD274 and non-small cell lung carcinoma.